Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

352 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Di Maio M, Leighl NB, Gallo C, Feld R, Ciardiello F, Butts C, Maione P, Gebbia V, Morgillo F, Wierzbicki R, Favaretto A, Alam Y, Cinieri S, Siena S, Bianco R, Riccardi F, Spatafora M, Ravaioli A, Felletti R, Fregoni V, Genestreti G, Rossi A, Mancuso G, Fasano M, Morabito A, Tsao MS, Signoriello S, Perrone F, Gridelli C. Di Maio M, et al. Among authors: feld r. J Thorac Oncol. 2012 Dec;7(12):1830-1844. doi: 10.1097/JTO.0b013e318275b327. J Thorac Oncol. 2012. PMID: 23154555 Free article. Clinical Trial.
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.
Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, Maione P, Morgillo F, Genestreti G, Favaretto A, Leighl N, Wierzbicki R, Cinieri S, Alam Y, Siena S, Tortora G, Felletti R, Riccardi F, Mancuso G, Rossi A, Cantile F, Tsao MS, Saieg M, da Cunha Santos G, Piccirillo MC, Di Maio M, Morabito A, Perrone F. Gridelli C, et al. Among authors: feld r. J Clin Oncol. 2012 Aug 20;30(24):3002-11. doi: 10.1200/JCO.2011.41.2056. Epub 2012 Jul 9. J Clin Oncol. 2012. PMID: 22778317 Clinical Trial.
Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.
Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F. Di Maio M, et al. Among authors: feld r. J Clin Oncol. 2015 Mar 10;33(8):910-5. doi: 10.1200/JCO.2014.57.9334. Epub 2015 Jan 26. J Clin Oncol. 2015. PMID: 25624439 Free article. Clinical Trial.
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients.
Kim L, Saieg M, Di Maio M, Gallo C, Butts C, Ciardiello F, Feld R, Cheng D, Gebbia V, Burgio MA, Alam Y, Signoriello S, Rossi A, Leighl N, Maione P, Morabito A, Liu G, Tsao MS, Perrone F, Gridelli C. Kim L, et al. Among authors: feld r. Oncotarget. 2017 Feb 25;8(34):57528-57536. doi: 10.18632/oncotarget.15725. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915692 Free PMC article.
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial.
Gridelli C, Butts C, Ciardiello F, Feld R, Gallo C, Perrone F. Gridelli C, et al. Among authors: feld r. Clin Lung Cancer. 2008 Jul;9(4):235-8. doi: 10.3816/CLC.2008.n.037. Clin Lung Cancer. 2008. PMID: 18650174 Clinical Trial.
Uncommon EGFR mutations in advanced non-small cell lung cancer.
O'Kane GM, Bradbury PA, Feld R, Leighl NB, Liu G, Pisters KM, Kamel-Reid S, Tsao MS, Shepherd FA. O'Kane GM, et al. Among authors: feld r. Lung Cancer. 2017 Jul;109:137-144. doi: 10.1016/j.lungcan.2017.04.016. Epub 2017 Apr 27. Lung Cancer. 2017. PMID: 28577943 Review.
352 results